Helix BioPharma Corp. (HBP : TSX)
Common Stock
$1.50
CAD
+0.08 (5.63%)
Last updated: 2026-06-22
HBP
Helix BioPharma Corp.
WealthAwesomePerformance
1 Day
+5.63%
1 Week
+0.67%
1 Month
-7.98%
YTD
-37.50%
Key Statistics
Market Cap
$108.46M
52W High
$5.40
52W Low
$0.84
P/E Ratio
-
50 Day MA
$1.73
200 Day MA
$2.01
Beta
-0.38
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 6/22/2026 | $1.39 | $1.50 | $1.39 | $1.50 | $1.50 | 516 |
| 6/19/2026 | $1.40 | $1.42 | $1.40 | $1.42 | $1.42 | 1,114 |
| 6/18/2026 | $1.45 | $1.45 | $1.42 | $1.42 | $1.42 | 354 |
| 6/17/2026 | $1.49 | $1.49 | $1.48 | $1.49 | $1.49 | 300 |
| 6/16/2026 | $1.52 | $1.52 | $1.40 | $1.50 | $1.50 | 1,093 |
| 6/15/2026 | $1.50 | $1.50 | $1.46 | $1.49 | $1.49 | 700 |
| 6/12/2026 | $1.58 | $1.58 | $1.58 | $1.58 | $1.58 | 0 |
| 6/11/2026 | $1.58 | $1.58 | $1.58 | $1.58 | $1.58 | 300 |
| 6/10/2026 | $1.50 | $1.52 | $1.50 | $1.52 | $1.52 | 204 |
| 6/9/2026 | $1.52 | $1.53 | $1.50 | $1.50 | $1.50 | 302 |
Analyst Price Targets
Based on analyst covering HBP
Wall Street analysts forecast HBP stock price to rise 66.7% over the next 12 months.
Consensus
No RatingAvg. Target
C$2.50
+66.7% Upside
Current Price
C$1.50
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
38.0%
Annualized
90-Day Vol
72.4%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$1.25
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$1.41 | C$1.24 โ C$1.61 |
| 60 trading days | C$1.33 | C$1.11 โ C$1.60 |
| 90 trading days | C$1.25 | C$1.00 โ C$1.57 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Helix BioPharma Corp.
Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer; and LDOS007, which is in phase Ib/II for the treatment of lung cancer. It develops V-DOS47, an antibody-DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company has an agreement with metaShape Pharma AG for covering LEUMUNA, within the field of adipose tissue-related and metabolic diseases. Helix BioPharma Corp. was incorporated in 2008 and is headquartered in Vancouver, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-3.25M
- Profit Margin
- 0.00%
- ROE (TTM)
- -49.99%
- EPS (Diluted)
- -0.04
- Book Value
- 0.19
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
๐ Recent Splits
1-for-5
Aug 16, 2024
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About HBP
Articles Featuring HBP.TO
Latest articles and analysis covering HBP.TO
Why Helix BioPharma Corp. stock is skyrocketing today
Helix BioPharma Corp. has seen its stock price rise by 5.63%, closing at CA$1.50, indicating a positive shift in market sentiment for this biotech firm.
Why Helix BioPharma Corp. stock is tanking today
Helix BioPharma Corp. (HBP.TO) faced a challenging trading day, with its stock price dropping 1.41% to close at CA$1.40. Investors are left wondering about the company's ability to secure necessary funding amidst a tough market.
Why Helix BioPharma Corp. stock is sliding today
Helix BioPharma Corp. shares fell 4.70% in the latest trading session, reflecting ongoing financial challenges and investor uncertainty about its future direction.
Why Helix BioPharma Corp. stock is tanking today
Helix BioPharma Corp. (HBP.TO) is experiencing a decline in stock performance, closing down 0.67% at CA$1.49. The company faces significant challenges in securing capital to support its operations and development goals.
Why Helix BioPharma Corp. stock is plummeting today
Helix BioPharma Corp.'s stock has dropped significantly, closing at CA$1.49 after a 5.70% decline. With no recent positive developments, investors are left questioning the company's future.
Why Helix BioPharma Corp. stock is plummeting today
Helix BioPharma Corp. saw its stock price fall by 5.06% today, raising alarms among investors as the company navigates a challenging landscape with no recent positive news.
Why Helix BioPharma Corp. stock is sliding today
Helix BioPharma Corp. saw its stock price fall 3.16% in the latest trading session, closing at CA$1.53. This decline raises questions about the company's financial stability and future growth potential.
